HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Weingrill, E. Articles by Liebmann, P. M. Search for Related Content PubMed PubMed Citation Articles by Weingrill, E. Articles by Liebmann, P. M.

Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients’ pretreatment status

^* Division of Hematology, Department of Internal Medicine
^° Institute of Pathophysiology, Medical University Graz, Austria

Correspondence: Peter M. Liebmann, PhD, Institute of Pathophysiology, Centre of Molecular Medicine, Medical University Graz, Heinrichstrasse 31a, 8010 Graz, Austria. Phone: international +43.316.3807676. Fax: international +43.316.3809640. E-mail: peter.liebmann{at}meduni-graz.at

Roscovitine induced apoptosis in isolated B-chronic lymphocytic leukemia cells of 25 patients of whom nine with relapsed and seven with fludarabine-refractory disease. It was synergistic with alemtuzumab and restored sensitivity to alemtuzumab in initially alemtuzumab-resistant samples. Observed roscovitine-induced up-regulation of CD52 surface expression may be one of the underlying mechanisms for this synergism.

Key words: B-CLL, roscovitine, alemtuzumab, apoptosis, synergism.